Physician profile
Adam Bykowski
NPI 1427409317
$13,381.19
in general payments reported to CMS, 2019-2025
31 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,144 · 2020: $475 · 2021: $2,253 · 2022: $3,104 · 2023: $2,720 · 2024: $1,322 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,817 · Travel and Lodging: $451 · Gift: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,816.68 |
| Travel and Lodging | $451.44 |
| Gift | $137.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,939.23 | 2019-2025 | Impella |
| Boston Scientific Corporation | $2,413.47 | 2021-2025 | Rotablator Rotational Atherectomy System Console Kit, Opticross, General - Structural Heart |
| Abbott Laboratories | $1,146.04 | 2021-2025 | Mitraclip, Aveir, Diamondback Coronary |
| Acist Medical Systems, INC. | $1,041.00 | 2022-2025 | |
| Cardiovascular Systems INC. | $841.63 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $617.86 | 2019-2022 | |
| Inari Medical, INC. | $531.06 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $488.07 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $385.43 | 2022-2023 | Onyx Frontier |
| Zoll Circulation INC | $310.00 | 2022 | |
| Veryan Medical Incorporated | $283.66 | 2022-2023 | Biomimics 3d Vascular Stent System |
| Janssen Pharmaceuticals, INC | $280.80 | 2019-2022 | |
| Medtronic Vascular, INC. | $227.90 | 2019-2020 | |
| Astellas Pharma US INC | $198.00 | 2021 | |
| W. L. Gore & Associates, INC. | $169.09 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $156.92 | 2021-2022 | |
| Becton, Dickinson and Company | $140.35 | 2024 | Rotarexs 6 F X 135 Cm |
| Asahi Intecc USA, INC. | $131.05 | 2022 | |
| Bracco Diagnostics INC. | $124.96 | 2019 | |
| Penumbra, INC. | $124.55 | 2025 | Penumbra System |
| United Therapeutics Corporation | $124.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.55 | 2021 | |
| Ekos Corporation | $118.57 | 2019 | |
| Amgen INC. | $101.22 | 2019-2022 | |
| Philips North America LLC | $100.63 | 2021 | |
| Bard Peripheral Vascular, INC. | $90.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $50.77 | 2019-2020 | |
| Angiodynamics, INC. | $48.25 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $33.42 | 2022 | |
| Pfizer INC. | $25.89 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bykowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.